{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:59:36Z","timestamp":1789160376877,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Vancomycin is an essential antibiotic for the treatment of severe gram-positive bacterial infections, including methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA). In critically ill patients, particularly children, attaining the appropriate dosage is crucial to avert drug resistance and ensure therapeutic efficacy. This study sought to investigate the pharmacokinetics of vancomycin in critically ill Asian pediatric patients and evaluate the influence of extracorporeal membrane oxygenation (ECMO) and disease severity on vancomycin clearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective analysis examined data from 90 critically ill Asian patients residing in Kaohsiung, Taiwan, encompassing 263 data points gathered over 2\u00a0years. A one-compartment pharmacokinetic model with first-order elimination was constructed using nonlinear mixed-effects modeling to assess the impact of ECMO and infection severity on vancomycin clearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The pharmacokinetics of vancomycin were markedly affected by ECMO and the severity of the illness. Patients using ECMO demonstrated a 56% decrease in vancomycin clearance relative to non-ECMO patients. Furthermore, patients with milder infections (e.g., cellulitis, surgical prophylaxis, neutropenic fever) had a 39% decrease in vancomycin clearance relative to those with more severe infections (e.g., pneumonia, bacteremia, osteomyelitis, meningitis, deep tissue infection).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study demonstrates that ECMO and infection severity are major factors influencing vancomycin clearance in critically unwell pediatric patients. The significant decrease in clearance linked to ECMO and reduced infection severity underscores the necessity for meticulous therapeutic drug monitoring and tailored dosing strategies to enhance vancomycin treatment in this at-risk population. The findings highlight the significant interindividual diversity in vancomycin pharmacokinetics in critically unwell pediatric patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1506793","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:33:09Z","timestamp":1740555189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetic effect of disease severity and use of extracorporeal membrane oxygenation in critically ill Asian patients receiving vancomycin"],"prefix":"10.3389","volume":"16","author":[{"given":"Charul","family":"Avachat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-lien","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Sherwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13318-021-00730-z","article-title":"Pharmacokinetics of vancomycin in critically ill children: a systematic review","volume":"47","author":"Akunne","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1136\/ejhpharm-2018-001720","article-title":"Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation","volume":"27","author":"An","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"538298","DOI":"10.3389\/fped.2020.538298","article-title":"Vancomycin prescribing practices and therapeutic drug monitoring for critically ill neonatal and pediatric patients: a survey of physicians and Pharmacists in Hong Kong","volume":"8","author":"Chow","year":"2020","journal-title":"Front. Pediatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1080\/13880209.2016.1183684","article-title":"Application of vancomycin in patients with varying renal function, especially those with augmented renal clearance","volume":"54","author":"Chu","year":"2016","journal-title":"Pharm. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.ekir.2021.01.037","article-title":"Pharmacokinetics of vancomycin in pediatric patients receiving intermittent Hemodialysis or hemodiafiltration","volume":"6","author":"Chung","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/FTD.0000000000000270","article-title":"Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance","volume":"38","author":"Hirai","year":"","journal-title":"Ther. Drug Monit."},{"key":"B7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/FTD.0000000000000346","article-title":"Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin","volume":"38","author":"Hirai","year":"","journal-title":"Ther. Drug Monit."},{"key":"B8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size standard for pharmacokinetics","volume":"30","author":"Holford","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1542\/peds.112.2.e104","article-title":"Vancomycin use in hospitalized pediatric patients","volume":"112","author":"Keyserling","year":"2003","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FTD.0000000000000941","article-title":"Therapeutic drug monitoring of antibiotic drugs in patients receiving continuous renal replacement therapy or intermittent Hemodialysis: a critical review","volume":"44","author":"Matusik","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"B12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/PCC.0000000000001682","article-title":"Population pharmacokinetics of vancomycin in pediatric extracorporeal membrane oxygenation","volume":"19","author":"Moffett","year":"2018","journal-title":"Pediatr. Crit. Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/jac\/dkab302","article-title":"Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations","volume":"76","author":"Shimamoto","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1586\/14787210.2014.966081","article-title":"Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections","volume":"12","author":"Stockmann","year":"2014","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/phar.1320","article-title":"Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis","volume":"33","author":"Stockmann","year":"2013","journal-title":"Pharmacotherapy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pedneo.2021.06.018","article-title":"Establishment and application of population pharmacokinetics model of vancomycin in infants with meningitis","volume":"63","author":"Xu","year":"2022","journal-title":"Pediatr. Neonatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e99044","DOI":"10.1371\/journal.pone.0099044","article-title":"Guidelines for therapeutic drug monitoring of vancomycin: a systematic review","volume":"9","author":"Ye","year":"2014","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijantimicag.2013.10.002","article-title":"Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012","volume":"43","author":"Yu","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1515\/med-2018-0068","article-title":"Pharmacokinetics of vancomycin in patients with different renal function levels","volume":"13","author":"Zaric","year":"2018","journal-title":"Open Med. (Wars)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5863\/1551-6776-23.4.305","article-title":"Therapeutic drug monitoring of vancomycin in pediatric patients with extracorporeal membrane oxygenation support","volume":"23","author":"Zylbersztajn","year":"2018","journal-title":"J. Pediatr. Pharmacol. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1506793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:33:11Z","timestamp":1740555191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1506793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":21,"alternative-id":["10.3389\/fphar.2025.1506793"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1506793","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"1506793"}}